Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jul 27;13:7213–7227. doi: 10.2147/OTT.S246471

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Shao et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

The association between the expression of the miR-3609/EPAS-1 axis with the prognosis of advanced HCC patients after receiving sorafenib treatment. The expression of EPAS-1 and miR-3609 in clinical specimens was examined, and the patients were divided into two groups according to the median expression level (high or low). The OS (overall survival) and TTP (time to progress) of patients were analyzed. (A and B) The prognosis of patients with high endogenous EPAS-1 expression (EPAS-1-high) or low endogenous EPAS-1 expression (EPAS-1-low). (C) The potential binding sites of miR-3609 in the 3′UTR of the epas-1 mRNA. (D and E) Prognosis of patients with high endogenous miR-3609 expression (miR-3609-high) or low endogenous miR-3609 expression (miR-3609-low); *P < 0.05.